Houston, Texas, August 20, 2026
FibroBiologics, Inc., a clinical-stage biotechnology company developing regenerative therapies based on fibroblast cells and fibroblast-derived materials, announced that IP Australia has accepted an Australian patent application covering a cannabidiol-based adjuvant approach for degenerative disc disease. The accepted patent application describes the use of cannabidiol in combination with fibroblast-based cell therapy and methods intended to enhance fibroblast regenerative activity. The development strengthens FibroBiologics’ intellectual property portfolio in regenerative medicine and supports its ongoing efforts to develop potential treatments for chronic degenerative diseases.
Patent Covers Cannabidiol and Fibroblast Combination
Australian Patent Application No. 2020368344, titled “Cannabidiol Adjuvant Therapy for Treatment of Disc Degenerative Disease,” covers methods of treating degenerative disc disease by administering cannabidiol together with a therapeutically effective amount of fibroblast cells. The application also describes the use of cannabidiol to potentially augment the regenerative activity of fibroblasts. According to the company, the accepted claims include approaches involving fibroblasts differentiated into notochord cells or chondrocytes, with the objective of supporting cells within the nucleus pulposus, the gel-like central region of an intervertebral disc. The patent represents an important intellectual property development for FibroBiologics as it expands its regenerative medicine programs targeting disc degeneration. The company said the approach is designed to combine the potential regenerative properties of fibroblast-based cell therapy with the proposed protective effects of cannabidiol on disc cells. Cannabidiol may be administered systemically, transdermally, or directly into the disc under the methods described in the patent application.
Regenerative Approach Targets Degenerative Disc Disease
Degenerative disc disease is associated with progressive changes to the intervertebral discs, including loss of hydration, structural integrity and cellular vitality. The condition can contribute to chronic back and neck pain, reduced mobility and impaired quality of life. Existing management approaches commonly focus on controlling symptoms through pain management and physical therapy, while more severe cases may require invasive surgical procedures. FibroBiologics is pursuing a regenerative strategy intended to address biological processes associated with disc degeneration rather than focusing solely on symptom management. Fibroblasts are connective-tissue cells involved in extracellular matrix remodeling and the production of various growth factors. The company is investigating their potential regenerative and immunomodulatory properties for chronic diseases and tissue degeneration. Under the newly accepted patent application, cannabidiol is intended to complement fibroblast therapy by potentially reducing apoptosis of disc cells and creating an environment that may support regeneration. The patent also covers cannabidiol’s proposed ability to enhance fibroblast production of growth factors, including IGF-1 and EGF-1.The company emphasized that the patent strengthens its position in disc degeneration, which is one of several clinical pathways within its broader development portfolio.
Advertisement
FibroBiologics Expands Regenerative Medicine Pipeline
The patent acceptance adds to FibroBiologics’ growing intellectual property portfolio, which the company reports includes more than 270 issued and pending patents across the United States and internationally. Its programs span areas including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, longevity and cancer. The company described the Australian patent development as part of its strategy to advance fibroblast-based cell therapies and fibroblast-derived materials for chronic diseases. The patent acceptance itself is an intellectual property milestone and does not establish clinical efficacy or regulatory approval of the proposed cannabidiol and fibroblast therapy for degenerative disc disease. Further research and clinical development would be required to determine whether the approach can demonstrate safety and therapeutic benefit in patients. FibroBiologics continues to develop its regenerative medicine pipeline while seeking to strengthen intellectual property protection for its therapeutic approaches. The Australian patent acceptance provides additional protection for its proposed cannabidiol-adjuvant fibroblast therapy and represents another step in the company’s efforts to develop regenerative solutions for degenerative conditions.
Source: FibroBiologics press relese
